Cargando…

Lenvatinib as first-line therapy for recurrent hepatocellular carcinoma after liver transplantation: Is the current evidence applicable to these patients?

Liver transplantation (LT) is one of the leading curative therapies for hepatocellular carcinoma (HCC). Despite recent optimization of transplant selection criteria, including alpha-feto protein, HCC recurrence after LT is still the leading cause of death in these patients. During the last decades,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Piñero, Federico, Thompson, Marcos, Marín, Juan Ignacio, Silva, Marcelo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2020
Materias:	Opinion Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708877/ https://www.ncbi.nlm.nih.gov/pubmed/33312891 http://dx.doi.org/10.5500/wjt.v10.i11.297

Ejemplares similares

Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantation
por: Bang, Kyunghye, et al.
Publicado: (2022)

The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment
por: Chan, Landon L., et al.
Publicado: (2023)

Trial eligibility in advanced hepatocellular carcinoma: Does it support clinical practice in underrepresented subgroups?
por: Piñero, Federico, et al.
Publicado: (2021)

Significance of progressive liver fibrosis in pediatric liver transplants: A review of current evidence
por: George, Mathew, et al.
Publicado: (2020)

Lenvatinib in elderly hepatocellular carcinoma patients, a new therapeutic option in first line
por: Roth, Gael S., et al.
Publicado: (2020)

Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study
por: Li, Qi, et al.
Publicado: (2022)

Efficacy and safety of lenvatinib for preventing tumor recurrence after liver transplantation in hepatocellular carcinoma beyond the Milan criteria
por: Guo, De-Zhen, et al.
Publicado: (2022)

SARS-CoV-2 vaccination in liver transplant recipients: We still haven't found what we are looking for
por: Thompson, Marcos A., et al.
Publicado: (2023)

Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
por: Wang, Shijie, et al.
Publicado: (2022)

Liver transplant outcomes during the COVID-19 pandemic
por: Mendizabal, Manuel, et al.
Publicado: (2022)

Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date
por: Personeni, Nicola, et al.
Publicado: (2019)

Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study
por: Zhao, Lei, et al.
Publicado: (2022)

Challenges to replace ACT as first-line drug
por: Phyo, Aung Pyae, et al.
Publicado: (2017)

Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors
por: Piñero, Federico, et al.
Publicado: (2020)

Cost-effectiveness analysis of transarterial chemoembolization combined with lenvatinib as the first-line treatment for advanced hepatocellular carcinoma
por: He, Ying, et al.
Publicado: (2023)

Efficacy and safety of lenvatinib versus sorafenib in first-line treatment of advanced hepatocellular carcinoma: A meta-analysis
por: Luo, Jia, et al.
Publicado: (2022)

Cost-effectiveness analysis of adding transarterial chemoembolisation to lenvatinib as first-line treatment for advanced hepatocellular carcinoma in China
por: Li, Wei, et al.
Publicado: (2023)

Efficacy and Safety of Lenvatinib in Hepatocellular Carcinoma Patients with Liver Transplantation: A Case-Control Study
por: Chen, Yen-Yang, et al.
Publicado: (2021)

Treating Thalassemia Patients with Luspatercept: An Expert Opinion Based on Current Evidence
por: Longo, Filomena, et al.
Publicado: (2023)

Efficacy of Lenvatinib and Sorafenib in the Real-World First-Line Treatment of Advanced-Stage Hepatocellular Carcinoma in a Taiwanese Population
por: Lee, Shou-Wu, et al.
Publicado: (2022)

Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first‐line treatment for unresectable hepatocellular carcinoma
por: Su, Chung‐Wei, et al.
Publicado: (2022)

Management of patients with liver diseases on the waiting list for transplantation: a major impact to the success of liver transplantation
por: Samuel, Didier, et al.
Publicado: (2018)

Low-dose PD-1 inhibitor combined with lenvatinib for preemptive treatment of recurrence after liver transplantation for hepatocellular carcinoma: Case report and literature review
por: Jin, Xin, et al.
Publicado: (2022)

Lenvatinib as second-line treatment in patients with unresectable hepatocellular carcinoma: A retrospective analysis
por: Qin, He-nan, et al.
Publicado: (2022)

Efficacy of HPV Vaccination Regarding Vulvar and Vaginal Recurrences in Previously Treated Women: The Need for Further Evidence
por: Bechini, Angela, et al.
Publicado: (2023)

Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study
por: Kim, Beom Kyung, et al.
Publicado: (2022)

Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma
por: Zhou, Ting, et al.
Publicado: (2022)

Atezolizumab plus bevacizumab versus lenvatinib as first-line therapy for advanced hepatocellular carcinoma: A systematic review and meta-analysis
por: Giri, Suprabhat, et al.
Publicado: (2023)

Lenvatinib Beyond First-Line Therapy in Patients With Advanced Biliary Tract Carcinoma
por: Wang, Yunchao, et al.
Publicado: (2022)

Successful resection after first‐line lenvatinib therapy in an advanced thymic carcinoma
por: Shimura, Masatoshi, et al.
Publicado: (2023)

Ancient Chinese Herbal Recipe Huanglian Jie Du Decoction for Ischemic Stroke: An Overview of Current Evidence
por: Yu, Chao-Chao, et al.
Publicado: (2022)

Successful hepatic resection for recurrent hepatocellular carcinoma after lenvatinib treatment: A case report
por: Yokoo, Hideki, et al.
Publicado: (2020)

Lenvatinib for Hepatocellular Carcinoma: A Literature Review
por: Hatanaka, Takeshi, et al.
Publicado: (2021)

The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma
por: Lee, Matthew Man Pok, et al.
Publicado: (2023)

Sorafenib as second‐line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma
por: Tomonari, Tetsu, et al.
Publicado: (2020)

Comparative study between sorafenib and lenvatinib as the first‐line therapy in the sequential treatment of unresectable hepatocellular carcinoma in a real‐world setting
por: Fukushima, Taito, et al.
Publicado: (2021)

Combined use of lactoferrin and vitamin D as a preventive and therapeutic supplement for SARS-CoV-2 infection: Current evidence
por: Cipriano, Massimiliano, et al.
Publicado: (2022)

Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma
por: He, Min-Ke, et al.
Publicado: (2021)

Real world evidence of Lenvatinib + anti PD-1 as an advanced line for metastatic melanoma
por: Stoff, Ronen, et al.
Publicado: (2023)

Growing body of evidence supports intrauterine insemination as first line treatment and rejects unfounded concerns about its efficacy, risks and cost effectiveness
por: Bahadur, Gulam, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_49gb0c8i3vukucs6kk36jlotbt